Little Richard F
HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bldg 10, Room 10S255, 9000 Rockville Pike, Bethesda, MD 20892-1868, USA.
Leuk Lymphoma. 2003;44 Suppl 3:S63-8. doi: 10.1080/10428190310001623748.
Lymphoproliferative disorders (LPD) occur more frequently in the immunosuppressed host compared to those who are immunocompetent. The biological and clinical characteristics of a particular LPD are specific to the underlying immune defect, though there are clear similarities in the various tumor types that occur. Immunosuppression-related LPD are more frequently associated with gamma-herpesviruses suggesting that the immunologic environment influences tumorigenesis. Clinical outcomes may be optimized when appropriate treatment strategies are based on consideration of the underlying immunodeficiency and on the tumor biology. Consistent with this observation, in AIDS-related lymphomas (ARL), tumor biology, clinical presentations, and treatment outcomes are correlated with the CD4 cell count. This review will consider the role of immune deficiency in HIV disease on ARL pathogenesis and epidemiology, and the impact that highly active antiretroviral therapy has had in this disease.
与免疫功能正常的宿主相比,免疫抑制宿主中淋巴增殖性疾病(LPD)的发生率更高。特定LPD的生物学和临床特征取决于潜在的免疫缺陷,尽管所发生的各种肿瘤类型存在明显的相似之处。免疫抑制相关的LPD更常与γ-疱疹病毒相关,这表明免疫环境会影响肿瘤发生。当基于对潜在免疫缺陷和肿瘤生物学的考虑制定适当的治疗策略时,临床结局可能会得到优化。与这一观察结果一致,在艾滋病相关淋巴瘤(ARL)中,肿瘤生物学、临床表现和治疗结局与CD4细胞计数相关。本综述将探讨HIV疾病中的免疫缺陷在ARL发病机制和流行病学中的作用,以及高效抗逆转录病毒疗法对该疾病的影响。